Anthrax News and Research

RSS
Anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis. Anthrax most commonly occurs in wild and domestic lower vertebrates (cattle, sheep, goats, camels, antelopes, and other herbivores), but it can also occur in humans when they are exposed to infected animals or tissue from infected animals.

Anthrax is most common in agricultural regions where it occurs in animals. These include South and Central America, Southern and Eastern Europe, Asia, Africa, the Caribbean, and the Middle East. When anthrax affects humans, it is usually due to an occupational exposure to infected animals or their products. Workers who are exposed to dead animals and animal products from other countries where anthrax is more common may become infected with B. anthracis (industrial anthrax). Anthrax outbreaks occur in the United States on an annual basis in livestock and wild game animals such as deer.

Anthrax infection can occur in three forms: cutaneous (skin), inhalation, and gastrointestinal. B. anthracis spores can live in the soil for many years, and humans can become infected with anthrax by handling products from infected animals or by inhaling anthrax spores from contaminated animal products. Anthrax can also be spread by eating undercooked meat from infected animals. It is rare to find infected animals in the United States.
Nanotechnology firm to develop test for handheld biosensors to detect deadly pathogens

Nanotechnology firm to develop test for handheld biosensors to detect deadly pathogens

New sensor can detect glucose levels in human saliva

New sensor can detect glucose levels in human saliva

Presidential Commission for the Study of Bioethical Issues to hold public meeting in San Francisco

Presidential Commission for the Study of Bioethical Issues to hold public meeting in San Francisco

Soligenix reports results from long-term stability studies of SGX204 anthrax vaccine

Soligenix reports results from long-term stability studies of SGX204 anthrax vaccine

Non-toxin vaccine shows promise against lethal anthrax infection

Non-toxin vaccine shows promise against lethal anthrax infection

Progress report on commercialization of BENLYSTA to be announced at JPMorgan Healthcare Conference

Progress report on commercialization of BENLYSTA to be announced at JPMorgan Healthcare Conference

Anthrax defenses need to be strengthened say experts

Anthrax defenses need to be strengthened say experts

New center for advanced emergency response to inaugurate on Jan. 6 at RUMC

New center for advanced emergency response to inaugurate on Jan. 6 at RUMC

Report: Funding cuts put public health preparedness at risk

Report: Funding cuts put public health preparedness at risk

Virus with potential for bioterrorism created – Experts worried

Virus with potential for bioterrorism created – Experts worried

Delaware Court upholds original ruling in favor of PharmAthene

Delaware Court upholds original ruling in favor of PharmAthene

Soligenix secures Harvard option rights to initiate anthrax vaccine development program

Soligenix secures Harvard option rights to initiate anthrax vaccine development program

Study identifies tertiary treatment as an important source of antibiotic resistant genes

Study identifies tertiary treatment as an important source of antibiotic resistant genes

Study reveals previously unseen details of SBP8a anthrax bacteriophage

Study reveals previously unseen details of SBP8a anthrax bacteriophage

H2S plays a major role in protecting bacteria from effects of different antibiotics

H2S plays a major role in protecting bacteria from effects of different antibiotics

iBio receives U.S. patent entitled 'System for Expression of Genes in Plants'

iBio receives U.S. patent entitled 'System for Expression of Genes in Plants'

Panel backs anthrax vaccine testing on children

Panel backs anthrax vaccine testing on children

NK cells can fight against anthrax

NK cells can fight against anthrax

Four companies receive NIAID contracts to develop broad-spectrum therapeutics

Four companies receive NIAID contracts to develop broad-spectrum therapeutics

Emergent BioSolutions receives $1.25B contract to supply 44.75M doses of BioThrax

Emergent BioSolutions receives $1.25B contract to supply 44.75M doses of BioThrax